China National Pharmaceutical Group Corporation: Subsidiary's Registration Certificate for Metoprolol Hydrochloride Tablets Approved

State Drug Administration announced that recently its wholly-owned subsidiary, Guoyao Rongsheng, received the "Drug Registration Certificate" issued by the National Medical Products Administration for Metoprolol Hydrochloride Tablets. Metoprolol Hydrochloride Tablets are used to treat primary hypertension and secondary hypertension caused by renal parenchymal disease. According to the Minew database, the sales of Metoprolol Hydrochloride Tablets in public medical institutions nationwide in 2024 were RMB 25.45 million. As of now, Guoyao Rongsheng has invested approximately RMB 7.717 million in research and development for this project. The registration of this drug and its acceptance through consistency evaluation will enhance the company's market competitiveness in the cardiovascular drug field. These matters will not have a significant impact on the company's current business performance.